USPTO serial 97881034
PENTEC HEALTH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 17, 2026
- Examiner
- FERRELL, LUCY K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PENTEC HEALTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David P. Fitzgibbon
David P. Fitzgibbon STRADLEY RONON STEVENS & YOUNG, LLP30 VALLEY STREAM PARKWAYMALVERN, PA 19355United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Oral nutritional supplements; dietetic foods adapted for medical use; parenteral nutrition delivered intravenously to treat patients with clinical nutritional deficiences; enteral nutrition formulas used to treat individuals with inborn errors of metabolism and metabolic conditions; vials containing compounded sterile preparations in the nature of sterile pharmaceutical preparations for renal patients, wound care patients, pain and spasticity patients, patients with implanted intrathecal pumps, patients with implanted hepatic artery pumps, patients with diabetes, patients with clinical nutrition deficiencies, and cancer patients; syringes containing compounded sterile preparations in the nature of sterile pharmaceutical preparations for renal patients, wound care patients, pain and spasticity patients, patients with implanted intrathecal pumps, patients with implanted hepatic artery pumps, patients with diabetes, patients with clinical nutrition deficiencies, and cancer patients | ACTIVE | Jun 1, 2023 |
| 035 | Pharmaceutical services, namely, processing prescription drug orders in closed-door, sterile, compounding pharmacies; specialized closed-door, sterile, compounding pharmacy services, namely, processing prescription drug orders for renal patients, wound care patients, pain and spasticity patients, patients with implanted intrathecal pumps, patients with implanted hepatic artery pumps, patients with diabetes, patients with clinical nutrition deficiencies, and cancer patients; consulting services, namely, providing consumer information about health care plans | ACTIVE | Jun 1, 2023 |
| 036 | Providing information regarding health care claim insurance, claim information, and payment options to health care providers, insurers, and consumers | ACTIVE | Jun 1, 2023 |
| 041 | Educational services, namely, providing educational seminars to industry healthcare professionals in the field of care of patients suffering from chronic kidney disease (CKD), end stage renal disease (ESRD), diabetes, intractable pain, and spasticity conditions, gastrointestinal disorders, clinical nutrition deficiencies related to chronic diseases, and cancer | ACTIVE | Jun 1, 2023 |
| 044 | Pharmaceutical advice for renal clinics, pain and spasticity management physician practices, nephrologists, dietitians, and oncologists; specialized closed-door, sterile, compounding pharmacy services, namely, pharmaceutical compounding services for renal patients, wound care patients, pain and spasticity patients, patients with implanted intrathecal pumps, patients with implanted hepatic artery pumps, patients with diabetes, patients with clinical nutrition deficiencies, and cancer patients; healthcare, namely, providing specialty infusion therapy for renal patients, wound care patients, patients with implanted intrathecal pumps, patients with implanted hepatic artery pumps, pain and spasticity patients, patients with diabetes, patients with clinical nutrition deficiencies, and cancer patients; providing healthcare services featuring supplemental oral nutrition therapy, nutrition therapy, nutrition counseling, and medical food therapy programs to patients and healthcare providers; Health care services for treating patients with clinical nutrition deficiencies by providing medical food formulated for administration under medical supervision | ACTIVE | Jun 1, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Pentec Health, Inc.
- Other trademarks owned by Pentec Health, Inc.
- Other trademarks owned by Pentec Health, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 041
- Other trademarks in Class 044
- Similar marks named PENTEC HEALTH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 17, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 17, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 28, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 28, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 8, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 8, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 3, 2025 | IUAF | USE AMENDMENT FILED | — |
| Jul 3, 2025 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 7, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 7, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 6, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jan 6, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 6, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 6, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 9, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 14, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 14, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 9, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 9, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 9, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 9, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 6, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 4, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 4, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 5, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 4, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 13, 2023 | NWAP | NEW APPLICATION ENTERED | — |